Bejelentkezés Regisztrálj ingyen

4SC AG Ret. a saját tőke

Mi az 4SC AG Ret. a saját tőke?

A Ret. a saját tőke az 4SC AG - -44.35%

Mi a Ret. a saját tőke meghatározása?



A saját tőke megtérülése egy vállalkozás nyereségességének mértéke a részvényes saját tőkéjének könyv szerinti értékéhez viszonyítva. Ezt úgy számítják ki, hogy a pénzügyi év nettó eredményét a teljes részvényes tőkével osztják el.

The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.

Ret. a saját tőke a Health Care szektor a XETRA-on cégekben a 4SC AG -hoz képest

Mit csinál 4SC AG?

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.

ret. a saját tőke -hoz hasonló cégek 4SC AG